Search

Displaying results 3681 - 3690 of 3730 in total
  1. Drug

    Cinnamon oil

    go.drugbank.com/drugs/DB15986
    ApprovedInvestigational

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  2. Drug

    JBPOS0101

    go.drugbank.com/drugs/DB16034
    Investigational

    JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  3. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulato...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  4. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Nafithromycin

    go.drugbank.com/drugs/DB16246
    Investigational

    Nafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  6. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC). Odevixibat is the first approv...

    Categories: P-glycoprotein substrates
  7. Drug

    Osalmid

    go.drugbank.com/drugs/DB16273
    Investigational

    Osalmid is under investigation in clinical trial NCT03670173 (Safety and Efficacy Assessments of Osalmid in Multiple Myeloma).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Vitis vinifera seed

    go.drugbank.com/drugs/DB16606
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  9. Drug

    Cepharanthine

    go.drugbank.com/drugs/DB16824
    Investigational

    Categories: P-glycoprotein inhibitors
  10. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    Tebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. Carbapenems are the standard treatme...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers